Why the study?
Does the DTaP-IPV-Hib (Pediacel) fully liquid pentavalent vaccine provide safe and effective immunization in children?
Does the DTaP-IPV-Hib (Pediacel) fully liquid pentavalent vaccine provide safe and effective immunization in children?
The fully liquid pentavalent vaccine DTaP-IPV-Hib (Pediacel) is a safe, effective, and immunogenic option for primary and booster pediatric immunization schedules based on 18 years of data.
Supports Pediacel in pediatric schedules; leaves open need for prospective validation amid evolving epidemiology.
Safe and effective combination pediatric vaccines are necessary to simplify complex immunization schedules and to improve coverage and protection for children worldwide. We provide an overview of the 18 years of clinical and worldwide experience with DTaP-IPV-Hib (Pediacel(®)), a unique fully liquid pentavalent vaccine (diphtheria [D], tetanus [T], acellular pertussis, inactivated poliovirus [IPV], Haemophilus influenzae type b [Hib]). Pediacel has demonstrated good and lasting immunogenicity in many populations, with differing primary series and booster schedules, and with a variety of coadministered vaccines. The acellular pertussis antigens have proven efficacy and real-world effectiveness. Clinical and post-marketing studies confirm the safety of Pediacel. Pediacel can be used for primary series and toddler booster doses, as well as in mixed pediatric vaccine schedules.
No takes yet. Share an insight, caveat, or question.
Reynolds et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: